The Centers for Medicare and Medicaid Services (CMS) is currently accepting public comments on the proposed national coverage determination for the first ever immunotherapy treatment for prostate cancer, Provenge.
Patients, medical, scientific and advocacy communities made it clear during CMS’ National Coverage Analysis that Provenge is an important treatment option for prostate cancer patients to have access to. Advocates took action with an unprecedented number of public comments made, over 90% in support of national coverage. But we still need your voice! CMS is requesting public comments on this proposed determination and will make a final determination and issue a final decision memorandum after the public comment period.
The CMS proposed decision summary states: “The Centers for Medicare and Medicaid Services (CMS) proposes that the evidence is adequate to conclude that the use of autologous cellular immunotherapy treatment – sipuleucel-T; PROVENGE® improves health outcomes for Medicare beneficiaries with asymptomatic or minimally symptomatic metastatic castrate-resistant (hormone refractory) prostate cancer, and thus is reasonable and necessary for that indication under 1862(a)(1)(A) of the Social Security Act (the Act).”
Act today by submitting your public comments, the deadline is April 30th. And don’t forget to use the sharing tools on the side to share with friends, colleagues and family.